Procarbazine
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Procarbazine |
| FDA Approval | Yes |
| Used for | Glioblastoma |
| Clinical Trial Phase | Not specified |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Hematological toxicity, nausea, and neurological effects |
| OS without | Not specified |
| OS with | Not specified |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: Combination of Temodar and procarbazine showed a high percentage of tumor regressions, suggesting effectiveness.
From Ben Williams Book: Not specified
Loading comments...
